Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Sibenadet. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 18/20 | 0.98 |
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.98 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sibenadet SCHEMBL48983 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| Sibenadet SCHEMBL30438496 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| Sibenadet SCHEMBL678828 | 0.97 | ADRB2 (0.97) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| Hydrochloric Acid SCHEMBL8527365 | 0.93 | ABCB11 (0.92) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| SCHEMBL8528403 | 0.92 | ABCB11 (0.93) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| Hydrochloric Acid SCHEMBL8533852 | 0.91 | ADRB2 (0.82) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| SCHEMBL8528272 | 0.90 | ADRB2 (0.84) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| Hydrochloric Acid SCHEMBL7842790 | 0.90 | ADRB2 (0.80) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| Hydrochloric Acid SCHEMBL8533675 | 0.89 | ABCB11 (0.81) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| Hydrochloric Acid SCHEMBL7838099 | 0.89 | ABCB11 (0.81) | ADRB2ADRB1DRD2PDE4AABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| US-20240117303-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2024-04-11 | — | — | US | claimed |
| WO-2024019800-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-01-25 | — | — | WO | claimed |
| WO-2001012167-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 7-(2-AMINOETHYL)-BENZOTHIAZOLONE AND AN ANTICHOLINERGIC MUSCARINIC ANTAGONIST | ASTRAZENECA UK LIMITED (GB) | 2001-02-22 | — | — | WO | claimed |
| WO-2001012192-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A-(2-AMINOETHYL)-BENZOTHIAZOLONE AND DISODIUM CROMOGLYCATE OR NEDOCROMIL | ASTRAZENECA UK LIMITED (GB) | 2001-02-22 | — | — | WO | claimed |
| WO-2001011933-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 7-(2-AMINOETHYL)-BENZOTHIAZOLONE AND A PDE4 INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2001-02-22 | — | — | WO | claimed |
| WO-2001012191-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 7-(2-AMINOETHYL)-BENZOTHIAZOLONE AND A GLUCOCORTICOID | ASTRAZENECA UK LIMITED (GB) | 2001-02-22 | — | — | WO | claimed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| EP-2152341-B2 | ATOMIZER IN THE FORM OF AN INHALER FOR MEDICAL AEROSOL THERAPY | BOEHRINGER INGELHEIM PHARMA (DE) | 2025-04-02 | — | — | EP | disclosed |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240117303-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2005070887-A1 | BRONCHORELAXING COMPOUNDS | RESPIRATORIUS AB (SE) | 2005-08-04 | — | — | WO | disclosed |
| WO-2001012191-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 7-(2-AMINOETHYL)-BENZOTHIAZOLONE AND A GLUCOCORTICOID | ASTRAZENECA UK LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
| WO-2001012167-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 7-(2-AMINOETHYL)-BENZOTHIAZOLONE AND AN ANTICHOLINERGIC MUSCARINIC ANTAGONIST | ASTRAZENECA UK LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
| WO-2001011933-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 7-(2-AMINOETHYL)-BENZOTHIAZOLONE AND A PDE4 INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
| WO-2001012192-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A-(2-AMINOETHYL)-BENZOTHIAZOLONE AND DISODIUM CROMOGLYCATE OR NEDOCROMIL | ASTRAZENECA UK LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
| EP-0649418-B1 | 7-(2-AMINOETHYL)-BENZOTHIAZOLONES | ASTRA PHARMA PROD (GB) | 1998-10-28 | — | — | EP | disclosed |
| US-5648370-A | 7-(2-aminoethyl) benzothiazolones | ASTRA PHARMACEUTICALS LIMITED (GB) | 1997-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | ADRB2 55/4885ADRB1 90/4885DRD2 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.